

specification pages 15-15A, 16-16A, 17-17A, 21, 24, 34 and 148, respectively*.

REMARKS

In the application as originally filed SEQ ID NO: 1768 was inadvertently assigned to both the last sequence of Table 18 and the first sequence of Table 19 (see page 148). Accordingly, applicants have designated the second sequence SEQ ID NO: 4340. Applicants have amended claim 7 in accordance with the correction to the sequence identifier for the first sequence presented in Table 19 of the application as filed.

Applicants have amended the specification pursuant to 37 C.F.R. § 1.52(e)(5) to incorporate by reference the Sequence Listing submitted in duplicate herewith on compact disc. Applicants have amended the specification to insert SEQ ID NO: 4340 in Table 19 and to insert reference in the text to the SEQ ID NOS: corresponding to the enclosed Sequence Listing.

In accordance with 37 C.F.R. §§ 1.52(e) and 1.821-1.825, applicants submit herewith both a written Sequence Listing on compact disc and a 3.5-inch floppy diskette with a computer-readable form (CRF) copy of a Sequence Listing and the required Statements under 37 C.F.R. §§ 1.821-1.825.

* Applicants have enclosed a marked up copy of the substitute pages of the specification. The portions added with this amendment are underscored.

The Sequence Listing contains 4,385 sequences. Support for SEQ ID NOS: 1-4340 can be found in Tables 10-32 of the originally filed application. Support for SEQ ID NOS: 4341 to 4368 can be found in figures of the originally filed application as follows:

<u>SEQ ID NO:</u>	<u>Support</u>	<u>SEQ ID NO:</u>	<u>Support</u>
4341	FIG. 1C	4355	FIG. 4
4342	FIG. 1C	4356	FIG. 4
4343	FIG. 1D & 9	4357	FIG. 4
4344	FIG. 1D & 9	4358	FIG. 4
4345	FIG. 1D & 9	4359	FIG. 7A-7B
4346	FIG. 1D & 9	4360	FIG. 7A
4347	FIG. 1D	4361	FIG. 7A-7B
4348	FIG. 1D	4362	FIG. 7B
4349	FIG. 2	4363	FIG. 8
4350	FIG. 3	4364	FIG. 8
4351	FIG. 3	4365	FIG. 8
4352	FIG. 3	4366	FIG. 8
4353	FIG. 3	4367	FIG. 8
4354	FIG. 3	4368	FIG. 9

SEQ ID NOS: 4369-4376 set forth the nucleic acid sequences of oligonucleotide primers. Support for SEQ ID NOS: 4369-4376 may be found on page 17, lines 21-26 of the application as originally filed.

SEQ ID NOS: 4377-4381 set forth the DNA sequences of synthetic oligonucleotides used for targeted gene alteration. Support for SEQ ID NOS: 4377-4381 may be found

on page 24, lines 10-25 of the application as originally filed.

SEQ ID NOS: 4382-4384 set forth the DNA sequences of synthetic oligonucleotides used for targeted gene alteration. Support for SEQ ID NOS: 4382-4384 may be found on page 34, lines 12-18 of the application as originally filed.

SEQ ID NO: 4385 sets forth the amino acid sequence of the FLASH peptide sequence. Support for SEQ ID NO: 4385 may be found on page 21, line 27 of the application as originally filed.

None of these amendments adds new matter. Their entry is requested.

The Response to the Notice to File Missing Parts

The Notice states that applicants must provide an executed oath or declaration and pay the fee set forth under 37 C.F.R. § 1.16(e). Accordingly, applicants enclose an executed Declaration and Power of Attorney signed by the inventors in compliance with 37 C.F.R. § 1.63 and a check in the amount of \$65.00 in payment of the required fee.

The Notice states that substitute drawings in compliance with 37 C.F.R. § 1.84 are required because the drawing sheets do not have the appropriate margin(s). Accordingly, applicants submit herewith twelve (12) substitute sheets of formal drawings.

The Notice further states that the nucleotide and/or amino acid disclosure fails to comply with the requirements of 37 C.F.R. § 1.821-1.825 because it does not contain (1) a paper copy of the Sequence Listing and (2) a computer readable form (CRF) copy of the Sequence Listing. As described above, applicants submit herewith an initial written copy of the Sequence Listing on compact disc and an initial CRF copy of the Sequence Listing in accordance with the requirements under 37 C.F.R. §§ 1.52(e), 1.821 and 1.824. Applicants further submit the required Statements under 37 C.F.R. §§ 1.825(f) and 1.825(g) that the written copy of the Sequence Listing filed on compact disc and the CRF copy of the Sequence Listing are identical to each other and contain no new matter.

The Director is hereby authorized to charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 06-1075. A duplicate copy of this response is enclosed.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Hope Liebke', is written over a horizontal line.

Hope Liebke (Reg. No. 35,588)
Attorney for Applicants
Grant Kalinowski (Reg. No. P-48,314)
Agent for Applicants
c/o FISH & NEAVE
1251 Avenue of the Americas
New York, New York 10020
United States of America
Tel.: (212) 596-9000
Fax: (212) 596-9090

Version Showing Changes Made

7. The oligonucleotide according to any one of claims 1 to 6, wherein the sequence of said oligonucleotide is selected from the group consisting of SEQ ID NOS: [1-4339] 1-4340.